1,2,3,8,9,9a-hexahydro-5H-pyrrolo[1,2-a]azepin-5-one Derivatives Useful As Factor XIa Inhibitors

A compound of formula (I)

• wherein
• R1 is selected from the group consisting of halogen, hydroxy, C1-4alkyl, fluorinated C1-4alkyl, C1-4alkoxy, fluorinated C1-4alkoxy, cyano, nitro, —NRARB, —C(O)—C1-4alkyl, C3-6cycloalkyl, phenyl and 5 to 6 membered heterocyclyl;
• wherein the C3-6cycloalkyl, phenyl or 5 to 6 membered heterocyclyl is optionally substituted with one or more substituents independently selected from the group consisting of halogen, hydroxy, cyano, C1-4alkyl, fluorinated C1-4alkyl, C1-4alkoxy, fluorinated C1-4alkoxy, —C(O)OH, —C(O)O—(C1-4alkyl), —NRARB, —(C1-4alkylene)-NRARB, C3-7cycloalkyl and 5 to 6 membered heterocyclyl;
• and wherein RA and RB are each independently selected from the group consisting of hydrogen and C1-4alkyl;
• a is an integer from 0 to 3;
• each R2 is independently selected from the group consisting of chloro, fluoro, methyl and methoxy;
• Q is selected from the group consisting of
• wherein R4 is selected from the group consisting of hydrogen, and halogen;
• wherein R5 is selected from the group consisting of phenyl and 5 to 6 membered heteroaryl;
• wherein the phenyl or 5 to 6 membered heteroaryl is optionally substituted with one to two substituents independently selected from the group consisting of halogen, C1-4alkyl, fluorinated C1-2alkyl, hydroxy substituted C1-2alkyl, —C(O)OH, —C(O)O—(C1-4alkyl), —NRCRD, —C(O)—NRCRD and —NRC—C(O)—(C1-2alkyl);
• and wherein RC and RD are each independently selected from the group consisting of hydrogen, C1-2alkyl and hydroxy substituted C1-4alkyl;
• and
• wherein R6 is selected from the group consisting of phenyl and 9 to 10 membered heteroaryl;
• wherein the phenyl or 9 to 10 membered heteroaryl is optionally substituted with one to two substituents independently selected from the group consisting of halogen, C1-4alkyl, fluorinated C1-2alkyl, hydroxy substituted C1-2alkyl, —C(O)OH, —C(O)O—(C1-4alkyl), —NRCRD, —C(O)—NRERF, and —NRC—C(O)—(C1-2alkyl);
• wherein RE and RF are each independently selected from the group consisting of hydrogen and C1-4alkyl;
• or a stereoisomer, isotopologue, or pharmaceutically acceptable salt thereof.